These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

747 related items for PubMed ID: 9409231

  • 1. Inhibition of HMG-CoA reductase by atorvastatin decreases both VLDL and LDL apolipoprotein B production in miniature pigs.
    Burnett JR, Wilcox LJ, Telford DE, Kleinstiver SJ, Barrett PH, Newton RS, Huff MW.
    Arterioscler Thromb Vasc Biol; 1997 Nov; 17(11):2589-600. PubMed ID: 9409231
    [Abstract] [Full Text] [Related]

  • 2. The magnitude of decrease in hepatic very low density lipoprotein apolipoprotein B secretion is determined by the extent of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition in miniature pigs.
    Burnett JR, Wilcox LJ, Telford DE, Kleinstiver SJ, Barrett PH, Newton RS, Huff MW.
    Endocrinology; 1999 Nov; 140(11):5293-302. PubMed ID: 10537160
    [Abstract] [Full Text] [Related]

  • 3. Inhibition of cholesterol esterification by DuP 128 decreases hepatic apolipoprotein B secretion in vivo: effect of dietary fat and cholesterol.
    Burnett JR, Wilcox LJ, Telford DE, Kleinstiver SJ, Barrett PH, Huff MW.
    Biochim Biophys Acta; 1998 Jul 31; 1393(1):63-79. PubMed ID: 9714740
    [Abstract] [Full Text] [Related]

  • 4. Inhibition of ACAT by avasimibe decreases both VLDL and LDL apolipoprotein B production in miniature pigs.
    Burnett JR, Wilcox LJ, Telford DE, Kleinstiver SJ, Barrett PH, Newton RS, Huff MW.
    J Lipid Res; 1999 Jul 31; 40(7):1317-27. PubMed ID: 10393217
    [Abstract] [Full Text] [Related]

  • 5. Inhibition of both the apical sodium-dependent bile acid transporter and HMG-CoA reductase markedly enhances the clearance of LDL apoB.
    Telford DE, Edwards JY, Lipson SM, Sutherland B, Barrett PH, Burnett JR, Krul ES, Keller BT, Huff MW.
    J Lipid Res; 2003 May 31; 44(5):943-52. PubMed ID: 12562847
    [Abstract] [Full Text] [Related]

  • 6. Differential regulation of apolipoprotein B secretion from HepG2 cells by two HMG-CoA reductase inhibitors, atorvastatin and simvastatin.
    Wilcox LJ, Barrett PH, Huff MW.
    J Lipid Res; 1999 Jun 31; 40(6):1078-89. PubMed ID: 10357840
    [Abstract] [Full Text] [Related]

  • 7. Lipid-lowering activity of atorvastatin and lovastatin in rodent species: triglyceride-lowering in rats correlates with efficacy in LDL animal models.
    Krause BR, Newton RS.
    Atherosclerosis; 1995 Oct 31; 117(2):237-44. PubMed ID: 8801869
    [Abstract] [Full Text] [Related]

  • 8. The HMG-CoA reductase inhibitor atorvastatin increases the fractional clearance rate of postprandial triglyceride-rich lipoproteins in miniature pigs.
    Burnett JR, Barrett PH, Vicini P, Miller DB, Telford DE, Kleinstiver SJ, Huff MW.
    Arterioscler Thromb Vasc Biol; 1998 Dec 31; 18(12):1906-14. PubMed ID: 9848883
    [Abstract] [Full Text] [Related]

  • 9. Mechanism of action of a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor on apolipoprotein B-100 kinetics in visceral obesity.
    Chan DC, Watts GF, Barrett PH, Mori TA, Beilin LJ, Redgrave TG.
    J Clin Endocrinol Metab; 2002 May 31; 87(5):2283-9. PubMed ID: 11994377
    [Abstract] [Full Text] [Related]

  • 10. Inhibition of hepatic ACAT decreases ApoB secretion in miniature pigs fed a cholesterol-free diet.
    Huff MW, Telford DE, Barrett PH, Billheimer JT, Gillies PJ.
    Arterioscler Thromb; 1994 Sep 31; 14(9):1498-508. PubMed ID: 8068612
    [Abstract] [Full Text] [Related]

  • 11. Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux.
    Guerin M, Egger P, Soudant C, Le Goff W, van Tol A, Dupuis R, Chapman MJ.
    Atherosclerosis; 2002 Aug 31; 163(2):287-96. PubMed ID: 12052475
    [Abstract] [Full Text] [Related]

  • 12. Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on apolipoprotein B100 metabolism in humans.
    Millar JS, Brousseau ME, Diffenderfer MR, Barrett PH, Welty FK, Faruqi A, Wolfe ML, Nartsupha C, Digenio AG, Mancuso JP, Dolnikowski GG, Schaefer EJ, Rader DJ.
    Arterioscler Thromb Vasc Biol; 2006 Jun 31; 26(6):1350-6. PubMed ID: 16574893
    [Abstract] [Full Text] [Related]

  • 13. Influence of atorvastatin and simvastatin on apolipoprotein B metabolism in moderate combined hyperlipidemic subjects with low VLDL and LDL fractional clearance rates.
    Forster LF, Stewart G, Bedford D, Stewart JP, Rogers E, Shepherd J, Packard CJ, Caslake MJ.
    Atherosclerosis; 2002 Sep 31; 164(1):129-45. PubMed ID: 12119202
    [Abstract] [Full Text] [Related]

  • 14. Hypocholesterolemic actions of atorvastatin are associated with alterations on hepatic cholesterol metabolism and lipoprotein composition in the guinea pig.
    Conde K, Vergara-Jimenez M, Krause BR, Newton RS, Fernandez ML.
    J Lipid Res; 1996 Nov 31; 37(11):2372-82. PubMed ID: 8978489
    [Abstract] [Full Text] [Related]

  • 15. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome.
    Watts GF, Barrett PH, Ji J, Serone AP, Chan DC, Croft KD, Loehrer F, Johnson AG.
    Diabetes; 2003 Mar 31; 52(3):803-11. PubMed ID: 12606523
    [Abstract] [Full Text] [Related]

  • 16. Hypocholesterolemic effects of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors in the guinea pig: atorvastatin versus simvastatin.
    Conde K, Pineda G, Newton RS, Fernandez ML.
    Biochem Pharmacol; 1999 Oct 01; 58(7):1209-19. PubMed ID: 10484079
    [Abstract] [Full Text] [Related]

  • 17. Inhibition of the apical sodium-dependent bile acid transporter reduces LDL cholesterol and apoB by enhanced plasma clearance of LDL apoB.
    Huff MW, Telford DE, Edwards JY, Burnett JR, Barrett PH, Rapp SR, Napawan N, Keller BT.
    Arterioscler Thromb Vasc Biol; 2002 Nov 01; 22(11):1884-91. PubMed ID: 12426220
    [Abstract] [Full Text] [Related]

  • 18. Attenuation of plasma low density lipoprotein cholesterol by select 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in mice devoid of low density lipoprotein receptors.
    Bisgaier CL, Essenburg AD, Auerbach BJ, Pape ME, Sekerke CS, Gee A, Wölle S, Newton RS.
    J Lipid Res; 1997 Dec 01; 38(12):2502-15. PubMed ID: 9458274
    [Abstract] [Full Text] [Related]

  • 19. Lipoprotein kinetics in male hemodialysis patients treated with atorvastatin.
    Schwaiger JP, Nakada Y, Berberich R, Ikewaki K, Dieplinger B, Zitt E, Neyer U, Salmhofer H, Kronenberg F, Koenig P, Dieplinger H.
    Clin J Am Soc Nephrol; 2013 Aug 01; 8(8):1319-26. PubMed ID: 23599405
    [Abstract] [Full Text] [Related]

  • 20. Lipid and apolipoprotein levels and distribution in patients with hypertriglyceridemia: effect of triglyceride reductions with atorvastatin.
    Le NA, Innis-Whitehouse W, Li X, Bakker-Arkema R, Black D, Brown WV.
    Metabolism; 2000 Feb 01; 49(2):167-77. PubMed ID: 10690940
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 38.